News

Systematic review findings point to bias and insufficient clinical applicability with current mortality risk models in patients with kidney failure.

In this episode, hosts discuss optimizing insulin therapy for people with diabetes using AI-driven algorithms with Eran Atlas, CEO of DreaMed Diabetes.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.

A study found that the protein ADM significantly mediates loneliness' link to cardiovascular disease, stroke, dementia, and mortality, emphasizing loneliness’ health risks.

These data highlight the connection between obesity, nutrition habits, and psycho-emotional status to the etiopathogenesis of seborrheic dermatitis.

In the inaugural episode of Skin of Color Savvy, Andrew Alexis, MD, MPH, and Shawn Kwatra, MD, discuss diagnosis and management of itch in skin of color.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Our Endocrinology Month in Review for December 2024 highlights recent headlines in diabetes and endocrinology and 4 new episodes of Diabetes Dialogue.

In this edition of HCPLive’s newsletter on monthly US Food and Drug Administration (FDA) news, we cover updates from across therapeutic pipelines in December.

Higher levels of small-particle HDL were linked with greater gray matter volume and higher cognitive capacity among middle-aged adults.

This study’s investigators examined long-term risk of dementia and Alzheimer’s dementia in patients with psoriasis, highlighting several notable findings.

This Psychiatry Month in Review features promising phase 3 data, what is moving in the pipeline, and where the psychiatry field is heading into 2025.

Zaheer discussed how this research may be used as a model to help study other therapy transitions as well.

A systematic review and meta-analysis of observational real-world data finds nearly half of patients who begin a GLP-1 RA will discontinue within a year.

The investigators assessed the proportion of households that chose to eliminate allergens by specific allergies to foods and to evaluate related psychosocial functioning among families.

A study found that NT-proBNP levels predict cardiovascular and renal risks in patients with advanced CKD and anemia. Greater NT-proBNP variability showed increased renal risks.

In this episode, hosts discuss a slight dip in US obesity rates, the use of inhaled insulin, and the benefit of mifepristone for HbA1c reduction.

In this analysis, baseline peanut sIgE was shown to be a stronger predictor of remission after peanut OIT than age at the beginning of immunotherapy treatment.

The December month in review spotlights hepatic FDA news as well as the latest research in viral hepatitis and MASH.

Bendapudi gave an overview of 2 studies presented at ASH 2024 from his Harvard lab.

Potassium nitrate increased blood nitric oxide metabolites but showed no improvement in exercise tolerance or quality of life in a population with HFpEF.

Although the oral navacaprant 80 mg failed to bring statistically significant improvements in depression symptoms, the study showed females respond better than males.

These data highlight long-term complications related to COVID-19 in terms of skin conditions, a continuing concern for many patients.

The December month in review spotlights top GI pipeline updates, FDA news, a feature, and IBS research from the final month of 2024.

Rani discussed an in-depth study examining quality of sleep and quality of life in children and adolescents with SCD.

A list recapping our most popular endocrinology coverage from the past year.

Patients hospitalized for severe COVID-19 had an accelerated eGFR decline relative to those with pneumonia due to other infections.